AtriCure, Inc. (ATRC) earnings
ATRC earnings moved a median of -0.89% by the close. Quarterly and annual ATRC reports and results, each read against the price at its own news timestamp. Back to the ATRC overview →
33 measured ATRC earnings events.
Where these ATRC earnings landedvs 33 measured ATRC earnings reactions
| Middle 50% of ATRC earnings reactions | -2.50% to +0.42% |
|---|---|
| Median reaction (to close) | -0.89% |
| Measured reactions | 33 |
Point-in-time · zero look-ahead
Half of the 33 ATRC earnings events with a measured close landed between -2.50% and +0.42%; 36% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| AtriCure to Announce Third Quarter 2026 Financial Results | Press release | -0.17% | -1.27% | |
| Form 10-Q AtriCure, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.09% | +0.16% | |
| AtriCure Reports Second Quarter 2026 Financial Results | Press release | -3.91% | +3.09% | |
| AtriCure to Announce Second Quarter 2026 Financial Results | Press release | +0.10% | +5.30% | |
| Form 10-Q AtriCure, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.44% | -0.89% | |
| AtriCure Reports First Quarter 2026 Financial Results | Press release | -0.84% | -0.11% | |
| AtriCure to Announce First Quarter 2026 Financial Results | Press release | +0.76% | +1.55% | |
| Form 10-K AtriCure, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.17% | -0.01% | |
| AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results | Press release | +0.68% | -0.25% | |
| Form 10-Q AtriCure, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.07% | -1.53% | |
| AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 | Press release | -12.99% | -7.51% | |
| AtriCure to Announce Third Quarter 2025 Financial Results | Press release | +0.00% | +2.13% | |
| Form 10-Q AtriCure, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.39% | -2.50% | |
| AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025 | Press release | -3.89% | -6.82% | |
| AtriCure to Announce Second Quarter 2025 Financial Results | Press release | +1.08% | +0.51% | |
| Form 10-Q AtriCure, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.10% | -1.39% | |
| AtriCure Reports First Quarter 2025 Financial Results | Press release | -0.79% | -4.07% | |
| AtriCure to Announce First Quarter 2025 Financial Results | Press release | -0.77% | -7.33% | |
| Form 10-K AtriCure, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.04% | +0.42% | |
| AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results | Press release | -6.07% | -5.74% | |
| Form 10-Q AtriCure, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.11% | -2.34% | |
| AtriCure Reports Third Quarter 2024 Financial Results | Press release | +0.19% | +1.25% | |
| AtriCure to Announce Third Quarter 2024 Financial Results | Press release | +0.00% | +0.89% | |
| Form 10-Q AtriCure, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.59% | -1.33% | |
| AtriCure Reports Second Quarter 2024 Financial Results | Press release | +0.91% | -1.96% | |
| AtriCure to Announce Second Quarter 2024 Financial Results | Press release | -0.83% | +2.16% | |
| Form 10-Q AtriCure, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.34% | +0.11% | |
| AtriCure Reports First Quarter 2024 Financial Results | Press release | -4.91% | -2.07% | |
| AtriCure to Announce First Quarter 2024 Financial Results | Press release | -0.23% | -2.60% | |
| Form 10-K AtriCure, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.41% | -0.01% | |
| AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results | Press release | -10.39% | -4.19% | |
| Form 10-Q AtriCure, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.45% | +0.27% | |
| AtriCure Reports Third Quarter 2023 Financial Results | Press release | -0.05% | -3.56% |
Keep exploring
More ATRC: analyst actions → · SEC filings → · ATRC overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CORREVIO PHARMA CORP ORDINARY SHARES (CORV) | 279 | 0.00% | 44% |
| Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF) | 278 | -0.48% | 36% |
| Coherus Oncology, Inc. (CHRS) | 276 | +0.21% | 51% |
| Xenon Pharmaceuticals Inc. - Common Shares (XENE) | 276 | +0.03% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.